Your browser doesn't support javascript.
loading
Deletion of TOP3ß, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders.
Stoll, Georg; Pietiläinen, Olli P H; Linder, Bastian; Suvisaari, Jaana; Brosi, Cornelia; Hennah, William; Leppä, Virpi; Torniainen, Minna; Ripatti, Samuli; Ala-Mello, Sirpa; Plöttner, Oliver; Rehnström, Karola; Tuulio-Henriksson, Annamari; Varilo, Teppo; Tallila, Jonna; Kristiansson, Kati; Isohanni, Matti; Kaprio, Jaakko; Eriksson, Johan G; Raitakari, Olli T; Lehtimäki, Terho; Jarvelin, Marjo-Riitta; Salomaa, Veikko; Hurles, Matthew; Stefansson, Hreinn; Peltonen, Leena; Sullivan, Patrick F; Paunio, Tiina; Lönnqvist, Jouko; Daly, Mark J; Fischer, Utz; Freimer, Nelson B; Palotie, Aarno.
  • Stoll G; Department of Biochemistry, University of Würzburg, Germany.
  • Pietiläinen OPH; Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
  • Linder B; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Suvisaari J; National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland.
  • Brosi C; Department of Biochemistry, University of Würzburg, Germany.
  • Hennah W; National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.
  • Leppä V; Department of Biochemistry, University of Würzburg, Germany.
  • Torniainen M; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Ripatti S; National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.
  • Ala-Mello S; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Plöttner O; National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.
  • Rehnström K; Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
  • Tuulio-Henriksson A; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Varilo T; Helsinki University Central Hospital, Department of Clinical Genetics, Helsinki, Finland.
  • Tallila J; Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany.
  • Kristiansson K; Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
  • Isohanni M; National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.
  • Kaprio J; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Eriksson JG; National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland.
  • Raitakari OT; Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
  • Lehtimäki T; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Jarvelin MR; Department of Psychiatry, Institute of Clinical Medicine, University of Oulu, Finland.
  • Salomaa V; Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
  • Hurles M; National Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.
  • Stefansson H; Department of Public Health, University of Helsinki, Helsinki, Finland.
  • Peltonen L; National Institute for Health and Welfare, Chronic Disease Epidemiology and Prevention, Helsinki, Finland.
  • Sullivan PF; Department of General Practice and Primary Health Care, University of Helsinki, Finland.
  • Paunio T; Vasa Central Hospital, Finland.
  • Lönnqvist J; Folkhälsan Research Centre, Helsinki, Finland.
  • Daly MJ; Unit of General Practice, Helsinki University Central Hospital, Finland.
  • Fischer U; Department of Clinical Physiology and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland.
  • Freimer NB; Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku and Turku University Central Hospital, Turku, Finland.
  • Palotie A; Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, Finland.
Nat Neurosci ; 16(9): 1228-1237, 2013 Sep.
Article en En | MEDLINE | ID: mdl-23912948
Implicating particular genes in the generation of complex brain and behavior phenotypes requires multiple lines of evidence. The rarity of most high-impact genetic variants typically precludes the possibility of accruing statistical evidence that they are associated with a given trait. We found that the enrichment of a rare chromosome 22q11.22 deletion in a recently expanded Northern Finnish sub-isolate enabled the detection of association between TOP3B and both schizophrenia and cognitive impairment. Biochemical analysis of TOP3ß revealed that this topoisomerase was a component of cytosolic messenger ribonucleoproteins (mRNPs) and was catalytically active on RNA. The recruitment of TOP3ß to mRNPs was independent of RNA cis-elements and was coupled to the co-recruitment of FMRP, the disease gene product in fragile X mental retardation syndrome. Our results indicate a previously unknown role for TOP3ß in mRNA metabolism and suggest that it is involved in neurodevelopmental disorders.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia / Anomalías Múltiples / Eliminación de Secuencia / Trastornos del Conocimiento / ADN-Topoisomerasas de Tipo I / Síndrome de DiGeorge Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2013 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia / Anomalías Múltiples / Eliminación de Secuencia / Trastornos del Conocimiento / ADN-Topoisomerasas de Tipo I / Síndrome de DiGeorge Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2013 Tipo del documento: Article